Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the ...

Living with asthma and related respiratory issues can be a nightmare, with attacks striking out of nowhere and no ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Excessive use of reliever inhalers for asthma is linked to a significantly increased risk of dying from the disease, a new study revealed today. Researchers found that over-use of short acting ...

The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990, the production of the bulk drug, cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik.

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...